Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDalteparin
Targets (4)
Enzymes (1)
Identification
- Name
- Dalteparin
- Accession Number
- DB06779
- Type
- Small Molecule
- Groups
- Approved
- Description
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
- Structure
- Synonyms
- alpha-heparin
- External IDs
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Dalteparin sodium 12M44VTJ7B Not Available Not applicable - Approved Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Fragmin Injection 5000 [iU]/.2mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US 
Fragmin Injection 5000 [iU]/.2mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Solution 10000 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada 
Fragmin Solution 5000 unit Intravenous; Subcutaneous Pfizer 1995-12-31 Not applicable Canada Fragmin Injection 10000 [iU]/.4mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 12500 [iU]/.5mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 12500 [iU]/.5mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Injection 2500 [iU]/.2mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Solution 18000 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Solution 7500 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Injection 25000 [iU]/mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Injection 2500 [iU]/.2mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 7500 [iU]/.3mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Injection 7500 [iU]/.3mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Solution 12500 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Solution 2500 unit Intravenous; Subcutaneous Pfizer 1995-12-31 Not applicable Canada Fragmin Injection 10000 [iU]/mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 15000 [iU]/.6mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 15000 [iU]/.6mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Solution 2500 unit Intravenous; Subcutaneous Pfizer 2012-07-25 Not applicable Canada Fragmin Solution 10000 unit Intravenous; Subcutaneous Pfizer 1995-12-31 Not applicable Canada Fragmin Injection 25000 [iU]/mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 10000 [iU]/mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 10000 [iU]/mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Solution 15000 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Solution 25000 unit Intravenous; Subcutaneous Pfizer 1997-11-27 Not applicable Canada Fragmin Injection 18000 [iU]/.72mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Injection 18000 [iU]/.72mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Solution 3500 unit Intravenous; Subcutaneous Pfizer 2015-03-25 Not applicable Canada Fragmin Inj.-liq 2500 Iu(anti-XA)/ml Liquid 2500 unit Intravenous; Subcutaneous Pharmacia & Upjohn Inc 1995-12-31 2002-07-30 Canada - Approved Generic Prescription Products
- Not Available
- Approved Over the Counter Products
- Not Available
- Unapproved/Other Products
- Not Available
- International/Other Brands
- Boxol (Pharmacia) / Eurodal (Gland) / Ligoframin (Pfizer) / Low Liquemine (Roche)
- Brand mixtures
- Not Available
- Categories
- UNII
- S79O08V79F
- CAS number
- 9005-49-6
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications.
Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).
It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
- Structured Indications
- Pharmacodynamics
Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
- Mechanism of action
Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage.
Target Actions Organism AAntithrombin-III potentiatorHuman AVascular endothelial growth factor A inhibitorHuman ATissue factor pathway inhibitor inhibitorHuman UP-selectin inhibitorHuman - Absorption
Almost completely absorbed after subcutaneous (sc) doses, with a bioavialability of about 87%.
- Volume of distribution
3 litres
- Protein binding
Less than unfractionated heparin, which is more than 90%.
- Metabolism
Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.
- Route of elimination
After 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).
- Half life
Terminal Half life: Intravenous - 2 hours. Subcutaneous - 3-5hours
- Clearance
Excreted via kidneys. The plasma clearance rate is 33 mL/min.
- Toxicity
Overdosage: hemorrhagic complications. Adverse Drug Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. (uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abciximab Abciximab may increase the anticoagulant activities of Dalteparin. Approved Aceclofenac Aceclofenac may increase the anticoagulant activities of Dalteparin. Approved Acenocoumarol Acenocoumarol may increase the anticoagulant activities of Dalteparin. Approved Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Adapalene Adapalene may increase the anticoagulant activities of Dalteparin. Approved Aliskiren Dalteparin may increase the hyperkalemic activities of Aliskiren. Approved, Investigational Allylestrenol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Allylestrenol. Approved Alprostadil Alprostadil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Alteplase Alteplase may increase the anticoagulant activities of Dalteparin. Approved Altrenogest The therapeutic efficacy of Dalteparin can be decreased when used in combination with Altrenogest. Vet Approved ALX-0081 ALX-0081 may increase the anticoagulant activities of Dalteparin. Investigational Amiloride Dalteparin may increase the hyperkalemic activities of Amiloride. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the anticoagulant activities of Dalteparin. Approved Anagrelide Anagrelide may increase the anticoagulant activities of Dalteparin. Approved Ancrod Ancrod may increase the anticoagulant activities of Dalteparin. Investigational Andrographolide HMPL-004 may increase the anticoagulant activities of Dalteparin. Investigational Anisodamine Anisodamine may increase the anticoagulant activities of Dalteparin. Investigational Anistreplase Anistreplase may increase the anticoagulant activities of Dalteparin. Approved Antipyrine Antipyrine may increase the anticoagulant activities of Dalteparin. Approved Antithrombin III human Dalteparin may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Apixaban may increase the anticoagulant activities of Dalteparin. Approved Apocynin Acetovanillone may increase the anticoagulant activities of Dalteparin. Investigational Apremilast Apremilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Aprotinin The therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin. Approved, Withdrawn Ardeparin Ardeparin may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Argatroban Argatroban may increase the anticoagulant activities of Dalteparin. Approved, Investigational Astaxanthin Astaxanthin may increase the anticoagulant activities of Dalteparin. Investigational Azapropazone Azapropazone may increase the anticoagulant activities of Dalteparin. Withdrawn Azelastine Azelastine may increase the anticoagulant activities of Dalteparin. Approved Azilsartan medoxomil Dalteparin may increase the hyperkalemic activities of Azilsartan medoxomil. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Dalteparin. Approved, Investigational Batroxobin Batroxobin may increase the anticoagulant activities of Dalteparin. Experimental Bazedoxifene Bazedoxifene may decrease the anticoagulant activities of Dalteparin. Approved, Investigational Becaplermin Becaplermin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Bemiparin Bemiparin may increase the anticoagulant activities of Dalteparin. Approved Benazepril Dalteparin may increase the hyperkalemic activities of Benazepril. Approved, Investigational Benoxaprofen Benoxaprofen may increase the anticoagulant activities of Dalteparin. Withdrawn Beraprost Beraprost may increase the anticoagulant activities of Dalteparin. Investigational Betulinic Acid Betulinic Acid may increase the anticoagulant activities of Dalteparin. Investigational Bivalirudin Bivalirudin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Bromfenac Bromfenac may increase the anticoagulant activities of Dalteparin. Approved Bucillamine Bucillamine may increase the anticoagulant activities of Dalteparin. Investigational Butylphthalide Butylphthalide may increase the anticoagulant activities of Dalteparin. Investigational Canagliflozin Dalteparin may increase the hyperkalemic activities of Canagliflozin. Approved Candesartan Dalteparin may increase the hyperkalemic activities of Candesartan. Approved Candoxatril Dalteparin may increase the hyperkalemic activities of Candoxatril. Experimental Cangrelor Cangrelor may increase the anticoagulant activities of Dalteparin. Approved Captopril Dalteparin may increase the hyperkalemic activities of Captopril. Approved Carprofen Carprofen may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved, Withdrawn Castanospermine Castanospermine may increase the anticoagulant activities of Dalteparin. Experimental Celecoxib Celecoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Certoparin Dalteparin may increase the anticoagulant activities of Certoparin. Approved Chloroquine Chloroquine may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Dalteparin. Withdrawn Choline magnesium trisalicylate Trisalicylate-choline may increase the anticoagulant activities of Dalteparin. Approved Cilazapril Dalteparin may increase the hyperkalemic activities of Cilazapril. Approved Cilostazol Cilostazol may increase the anticoagulant activities of Dalteparin. Approved Citric Acid Citric Acid may increase the anticoagulant activities of Dalteparin. Nutraceutical, Vet Approved Clonixin Clonixin may increase the anticoagulant activities of Dalteparin. Approved Clopidogrel Clopidogrel may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical Conjugated estrogens Conjugated Equine Estrogens may decrease the anticoagulant activities of Dalteparin. Approved Curcumin Curcumin may increase the anticoagulant activities of Dalteparin. Investigational D-Limonene D-Limonene may increase the anticoagulant activities of Dalteparin. Investigational Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Danaparoid may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Darexaban Dalteparin may increase the anticoagulant activities of Ym150. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Deferasirox The risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox. Approved, Investigational Defibrotide Defibrotide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Deoxycholic Acid The risk or severity of adverse effects can be increased when Dalteparin is combined with Deoxycholic Acid. Approved dersalazine dersalazine may increase the anticoagulant activities of Dalteparin. Investigational Desirudin Dalteparin may increase the anticoagulant activities of Desirudin. Approved Desmoteplase Desmoteplase may increase the anticoagulant activities of Dalteparin. Investigational Desogestrel The therapeutic efficacy of Dalteparin can be decreased when used in combination with Desogestrel. Approved Dextran Dalteparin may increase the anticoagulant activities of Dextran. Approved, Vet Approved Dextran 40 Dalteparin may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Dalteparin may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Dalteparin may increase the anticoagulant activities of Dextran 75. Approved Diclofenac Diclofenac may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Dicoumarol Dicoumarol may increase the anticoagulant activities of Dalteparin. Approved Dienestrol Dienestrol may decrease the anticoagulant activities of Dalteparin. Approved Dienogest The therapeutic efficacy of Dalteparin can be decreased when used in combination with Dienogest. Approved Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Dalteparin. Approved Diflunisal Diflunisal may increase the anticoagulant activities of Dalteparin. Approved Dipyridamole Dipyridamole may increase the anticoagulant activities of Dalteparin. Approved Ditazole Ditazole may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Drospirenone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Drospirenone. Approved Drotrecogin alfa Drotrecogin alfa may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Droxicam Droxicam may increase the anticoagulant activities of Dalteparin. Approved Duvelisib Duvelisib may increase the anticoagulant activities of Dalteparin. Investigational Dydrogesterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Dydrogesterone. Approved, Withdrawn E-6201 E6201 may increase the anticoagulant activities of Dalteparin. Investigational Ebselen Ebselen may increase the anticoagulant activities of Dalteparin. Investigational Edetic Acid Edetic Acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Edoxaban Edoxaban may increase the anticoagulant activities of Dalteparin. Approved Enalapril Dalteparin may increase the hyperkalemic activities of Enalapril. Approved, Vet Approved Enalaprilat Dalteparin may increase the hyperkalemic activities of Enalaprilat. Approved Enoxaparin Enoxaparin may increase the anticoagulant activities of Dalteparin. Approved Epinastine Epinastine may increase the anticoagulant activities of Dalteparin. Approved, Investigational Epirizole Epirizole may increase the anticoagulant activities of Dalteparin. Approved Eplerenone Dalteparin may increase the hyperkalemic activities of Eplerenone. Approved eplivanserine eplivanserine may increase the anticoagulant activities of Dalteparin. Investigational Epoprostenol Epoprostenol may increase the anticoagulant activities of Dalteparin. Approved Eprosartan Dalteparin may increase the hyperkalemic activities of Eprosartan. Approved Eptifibatide Eptifibatide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Equol S Equol may decrease the anticoagulant activities of Dalteparin. Investigational Estradiol Estradiol may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estriol Estriol may decrease the anticoagulant activities of Dalteparin. Approved, Vet Approved Estrone Estrone may decrease the anticoagulant activities of Dalteparin. Approved Etanercept Etanercept may increase the anticoagulant activities of Dalteparin. Approved, Investigational Ethinyl Estradiol Ethinyl Estradiol may decrease the anticoagulant activities of Dalteparin. Approved Ethyl biscoumacetate Dalteparin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethynodiol diacetate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Ethynodiol diacetate. Approved Etodolac Etodolac may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the anticoagulant activities of Dalteparin. Approved Etonogestrel The therapeutic efficacy of Dalteparin can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoricoxib Etoricoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the anticoagulant activities of Dalteparin. Approved exisulind exisulind may increase the anticoagulant activities of Dalteparin. Investigational Fenbufen Fenbufen may increase the anticoagulant activities of Dalteparin. Approved Fenoprofen Fenoprofen may increase the anticoagulant activities of Dalteparin. Approved Fibrinolysin Plasmin may increase the anticoagulant activities of Dalteparin. Investigational Floctafenine Floctafenine may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Fluindione Dalteparin may increase the anticoagulant activities of Fluindione. Investigational Flunixin Flunixin may increase the anticoagulant activities of Dalteparin. Vet Approved Flurbiprofen Flurbiprofen may increase the anticoagulant activities of Dalteparin. Approved, Investigational Fondaparinux Dalteparin may increase the anticoagulant activities of Fondaparinux. Investigational Fondaparinux sodium Fondaparinux sodium may increase the anticoagulant activities of Dalteparin. Approved, Investigational Forasartan Dalteparin may increase the hyperkalemic activities of Forasartan. Experimental Fosinopril Dalteparin may increase the hyperkalemic activities of Fosinopril. Approved Gabexate Dalteparin may increase the anticoagulant activities of Gabexate. Investigational Genistein Genistein may decrease the anticoagulant activities of Dalteparin. Investigational Gestodene The therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestodene. Approved Gestrinone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestrinone. Approved Hemin Hemin may increase the anticoagulant activities of Dalteparin. Approved Heparin Heparin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Hexestrol Hexestrol may decrease the anticoagulant activities of Dalteparin. Withdrawn Higenamine Higenamine may increase the anticoagulant activities of Dalteparin. Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Hydroxyprogesterone caproate. Approved Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan. Approved Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin. Approved Ibudilast Ibudilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Ibuprofen Ibuprofen may increase the anticoagulant activities of Dalteparin. Approved Ibuproxam Ibuproxam may increase the anticoagulant activities of Dalteparin. Withdrawn Icatibant Icatibant may increase the anticoagulant activities of Dalteparin. Approved Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical Idraparinux Dalteparin may increase the anticoagulant activities of idraparinux. Investigational Ifenprodil Ifenprodil may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Iloprost Iloprost may increase the anticoagulant activities of Dalteparin. Approved, Investigational Imidapril Dalteparin may increase the hyperkalemic activities of Imidapril. Investigational Indobufen Indobufen may increase the anticoagulant activities of Dalteparin. Investigational Indomethacin Indomethacin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Indoprofen Indoprofen may increase the anticoagulant activities of Dalteparin. Withdrawn Irbesartan Dalteparin may increase the hyperkalemic activities of Irbesartan. Approved, Investigational Isoxicam Isoxicam may increase the anticoagulant activities of Dalteparin. Withdrawn Kebuzone Kebuzone may increase the anticoagulant activities of Dalteparin. Experimental Ketanserin Ketanserin may increase the anticoagulant activities of Dalteparin. Investigational Ketoprofen Ketoprofen may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Ketorolac Ketorolac may increase the anticoagulant activities of Dalteparin. Approved Leflunomide Leflunomide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Lepirudin Lepirudin may increase the anticoagulant activities of Dalteparin. Approved Levonorgestrel The therapeutic efficacy of Dalteparin can be decreased when used in combination with Levonorgestrel. Approved, Investigational Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Dalteparin. Approved Lisinopril Dalteparin may increase the hyperkalemic activities of Lisinopril. Approved, Investigational Lisofylline Lisofylline may increase the anticoagulant activities of Dalteparin. Investigational Lornoxicam Lornoxicam may increase the anticoagulant activities of Dalteparin. Approved Losartan Dalteparin may increase the hyperkalemic activities of Losartan. Approved Loxoprofen Loxoprofen may increase the anticoagulant activities of Dalteparin. Approved Lumiracoxib Lumiracoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Lynestrenol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Lynestrenol. Investigational Magnesium salicylate Magnesium salicylate may increase the anticoagulant activities of Dalteparin. Approved Masoprocol Masoprocol may increase the anticoagulant activities of Dalteparin. Approved Meclofenamic acid Meclofenamic acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Medrogestone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Mefenamic acid Mefenamic acid may increase the anticoagulant activities of Dalteparin. Approved Megestrol acetate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Megestrol acetate. Approved, Vet Approved Meloxicam Meloxicam may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Dalteparin. Approved Mestranol Mestranol may decrease the anticoagulant activities of Dalteparin. Approved Metamizole Metamizole may increase the anticoagulant activities of Dalteparin. Withdrawn Methallenestril Methallenestril may decrease the anticoagulant activities of Dalteparin. Experimental Milrinone Milrinone may increase the anticoagulant activities of Dalteparin. Approved Mizoribine Mizoribine may increase the anticoagulant activities of Dalteparin. Investigational Moexipril Dalteparin may increase the hyperkalemic activities of Moexipril. Approved Mycophenolate mofetil Mycophenolate mofetil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the anticoagulant activities of Dalteparin. Approved Nabumetone Nabumetone may increase the anticoagulant activities of Dalteparin. Approved Nadroparin Dalteparin may increase the anticoagulant activities of Nadroparin. Approved Nafamostat Nafamostat may increase the anticoagulant activities of Dalteparin. Approved, Investigational Naftifine Naftifine may increase the anticoagulant activities of Dalteparin. Approved Naftopidil Naftopidil may increase the anticoagulant activities of Dalteparin. Investigational Naproxen Naproxen may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Nepafenac Nepafenac may increase the anticoagulant activities of Dalteparin. Approved Niflumic Acid Niflumic Acid may increase the anticoagulant activities of Dalteparin. Approved Nimesulide Nimesulide may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Nintedanib The risk or severity of adverse effects can be increased when Dalteparin is combined with Nintedanib. Approved Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Dalteparin. Investigational Nomegestrol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Nomegestrol. Approved Norethisterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Norethisterone. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab. Approved Olmesartan Dalteparin may increase the hyperkalemic activities of Olmesartan. Approved, Investigational Olopatadine Olopatadine may increase the anticoagulant activities of Dalteparin. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Dalteparin. Approved Omacetaxine mepesuccinate The risk or severity of adverse effects can be increased when Dalteparin is combined with Omacetaxine mepesuccinate. Approved Omapatrilat Dalteparin may increase the hyperkalemic activities of Omapatrilat. Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical Orgotein Orgotein may increase the anticoagulant activities of Dalteparin. Vet Approved Otamixaban Otamixaban may increase the anticoagulant activities of Dalteparin. Investigational Oxaprozin Oxaprozin may increase the anticoagulant activities of Dalteparin. Approved Oxyphenbutazone Oxyphenbutazone may increase the anticoagulant activities of Dalteparin. Withdrawn Ozagrel Kct 0809 may increase the anticoagulant activities of Dalteparin. Investigational Palifermin The serum concentration of Palifermin can be increased when it is combined with Dalteparin. Approved Parecoxib Parecoxib may increase the anticoagulant activities of Dalteparin. Approved Parnaparin Parnaparin may increase the anticoagulant activities of Dalteparin. Approved Pentosan Polysulfate Pentosan Polysulfate may increase the anticoagulant activities of Dalteparin. Approved Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Dalteparin. Approved, Investigational Perindopril Dalteparin may increase the hyperkalemic activities of Perindopril. Approved Phenindione Phenindione may increase the anticoagulant activities of Dalteparin. Approved Phenprocoumon Phenprocoumon may increase the anticoagulant activities of Dalteparin. Approved Phenylbutazone Phenylbutazone may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Pimecrolimus Pimecrolimus may increase the anticoagulant activities of Dalteparin. Approved, Investigational Pirfenidone Pirfenidone may increase the anticoagulant activities of Dalteparin. Investigational Piroxicam Piroxicam may increase the anticoagulant activities of Dalteparin. Approved, Investigational Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Dalteparin. Approved Prasugrel Prasugrel may increase the anticoagulant activities of Dalteparin. Approved Progesterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone. Approved, Vet Approved Promestriene Promestriene may decrease the anticoagulant activities of Dalteparin. Investigational Propacetamol Propacetamol may increase the anticoagulant activities of Dalteparin. Approved Protein C Dalteparin may increase the anticoagulant activities of Protein C. Approved Protein S human Dalteparin may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Dalteparin may increase the anticoagulant activities of Protocatechualdehyde. Approved PTC299 PTC299 may increase the anticoagulant activities of Dalteparin. Investigational Quinapril Dalteparin may increase the hyperkalemic activities of Quinapril. Approved, Investigational Quinestrol Quinestrol may decrease the anticoagulant activities of Dalteparin. Approved Ramatroban Ramatroban may increase the anticoagulant activities of Dalteparin. Investigational Ramipril Dalteparin may increase the hyperkalemic activities of Ramipril. Approved Rescinnamine Dalteparin may increase the hyperkalemic activities of Rescinnamine. Approved Resveratrol Resveratrol may increase the anticoagulant activities of Dalteparin. Experimental, Investigational Reteplase Reteplase may increase the anticoagulant activities of Dalteparin. Approved Reviparin Dalteparin may increase the anticoagulant activities of Reviparin. Approved Ridogrel Ridogrel may increase the anticoagulant activities of Dalteparin. Approved Rivaroxaban Dalteparin may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the anticoagulant activities of Dalteparin. Investigational, Withdrawn Rosiglitazone Rosiglitazone may increase the anticoagulant activities of Dalteparin. Approved, Investigational Sacubitril Dalteparin may increase the hyperkalemic activities of Sacubitril. Approved Salicylamide Salicylamide may increase the anticoagulant activities of Dalteparin. Approved Salicylic acid Salicylic acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Salsalate Salsalate may increase the anticoagulant activities of Dalteparin. Approved Saprisartan Dalteparin may increase the hyperkalemic activities of Saprisartan. Experimental Saralasin Dalteparin may increase the hyperkalemic activities of Saralasin. Investigational Secoisolariciresinol Secoisolariciresinol may decrease the anticoagulant activities of Dalteparin. Investigational Selexipag Selexipag may increase the anticoagulant activities of Dalteparin. Approved Seratrodast Seratrodast may increase the anticoagulant activities of Dalteparin. Approved Sevoflurane Sevoflurane may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Spirapril Dalteparin may increase the hyperkalemic activities of Spirapril. Approved Spironolactone Dalteparin may increase the hyperkalemic activities of Spironolactone. Approved SRT501 SRT501 may increase the anticoagulant activities of Dalteparin. Investigational Streptokinase Streptokinase may increase the anticoagulant activities of Dalteparin. Approved Sugammadex Sugammadex may increase the anticoagulant activities of Dalteparin. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dalteparin. Approved Sulindac Sulindac may increase the anticoagulant activities of Dalteparin. Approved Sulodexide Sulodexide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Suprofen Suprofen may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dalteparin. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin. Approved Tasosartan Dalteparin may increase the hyperkalemic activities of Tasosartan. Approved Telmisartan Dalteparin may increase the hyperkalemic activities of Telmisartan. Approved, Investigational Temocapril Dalteparin may increase the hyperkalemic activities of Temocapril. Experimental, Investigational Tenecteplase Tenecteplase may increase the anticoagulant activities of Dalteparin. Approved Tenoxicam Tenoxicam may increase the anticoagulant activities of Dalteparin. Approved Tepoxalin Tepoxalin may increase the anticoagulant activities of Dalteparin. Vet Approved Teriflunomide Teriflunomide may increase the anticoagulant activities of Dalteparin. Approved Tesmilifene Tesmilifene may increase the anticoagulant activities of Dalteparin. Investigational Tiaprofenic acid Tiaprofenic acid may increase the anticoagulant activities of Dalteparin. Approved Tibolone Tibolone may increase the anticoagulant activities of Dalteparin. Approved Ticagrelor Ticagrelor may increase the anticoagulant activities of Dalteparin. Approved Ticlopidine Ticlopidine may increase the anticoagulant activities of Dalteparin. Approved Tinoridine Tinoridine may increase the anticoagulant activities of Dalteparin. Investigational Tinzaparin Tinzaparin may increase the anticoagulant activities of Dalteparin. Approved Tipranavir Tipranavir may increase the anticoagulant activities of Dalteparin. Approved, Investigational Tirofiban Tirofiban may increase the anticoagulant activities of Dalteparin. Approved Tolfenamic Acid Tolfenamic Acid may increase the anticoagulant activities of Dalteparin. Approved Tolmetin Tolmetin may increase the anticoagulant activities of Dalteparin. Approved Tositumomab The risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab. Approved Trandolapril Dalteparin may increase the hyperkalemic activities of Trandolapril. Approved Tranilast Tranilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Trapidil Trapidil may increase the anticoagulant activities of Dalteparin. Approved Treprostinil Treprostinil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Triamterene Dalteparin may increase the hyperkalemic activities of Triamterene. Approved Triflusal Triflusal may increase the anticoagulant activities of Dalteparin. Approved Urokinase Urokinase may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Valdecoxib Valdecoxib may increase the anticoagulant activities of Dalteparin. Investigational, Withdrawn Valsartan Dalteparin may increase the hyperkalemic activities of Valsartan. Approved, Investigational Vitamin E Vitamin E may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical, Vet Approved Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Dalteparin. Approved Warfarin Warfarin may increase the anticoagulant activities of Dalteparin. Approved Ximelagatran Ximelagatran may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the anticoagulant activities of Dalteparin. Approved Zeranol Zeranol may decrease the anticoagulant activities of Dalteparin. Vet Approved Zileuton Zileuton may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Zomepirac Zomepirac may increase the anticoagulant activities of Dalteparin. Withdrawn - Food Interactions
- Herbs (anticoagulant/antiplatelet properties such as ginseng, ginkgo, ginger, garlic)
References
- Synthesis Reference
- Not Available
- General References
- King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr;100(4):535-40. [PubMed:6367579 ]
- Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980 Oct 16;303(16):902-7. [PubMed:6997743 ]
- Ockelford PA, Patterson J, Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046-9. [PubMed:2559484 ]
- Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577-84. [PubMed:2158151 ]
- Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A: Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol. 1989;37(4):415-8. [PubMed:2557219 ]
- Holmer E, Soderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16 Suppl 2:1-7. [PubMed:3744129 ]
- Malm K, Dahlback B, Arnljots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003 Apr 15;111(5):1659-66. [PubMed:12655212 ]
- Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006 Jul;91(7):976-9. Epub 2006 Jun 1. [PubMed:16757417 ]
- Schmid P, Brodmann D, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19. [PubMed:19175499 ]
- Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N: Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286-94. Epub 2006 Oct 25. [PubMed:17166617 ]
- Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
- Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. [PubMed:11011804 ]
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]
- External Links
- KEGG Drug
- D03353
- Wikipedia
- Dalteparin_sodium
- ATC Codes
- B01AB04 — Dalteparin
- AHFS Codes
- 20:12.04.16
- PDB Entries
- Not Available
- FDA label
- Not Available
- MSDS
- Not Available
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection Subcutaneous 10000 [iU]/.4mL Injection Subcutaneous 10000 [iU]/mL Injection Subcutaneous 12500 [iU]/.5mL Injection Subcutaneous 15000 [iU]/.6mL Injection Subcutaneous 18000 [iU]/.72mL Injection Subcutaneous 2500 [iU]/.2mL Injection Subcutaneous 25000 [iU]/mL Injection Subcutaneous 5000 [iU]/.2mL Injection Subcutaneous 7500 [iU]/.3mL Solution Intravenous; Subcutaneous 10000 unit Solution Intravenous; Subcutaneous 12500 unit Solution Intravenous; Subcutaneous 15000 unit Solution Intravenous; Subcutaneous 18000 unit Solution Intravenous; Subcutaneous 2500 unit Solution Intravenous; Subcutaneous 25000 unit Solution Intravenous; Subcutaneous 3500 unit Solution Intravenous; Subcutaneous 5000 unit Solution Intravenous; Subcutaneous 7500 unit Liquid Intravenous; Subcutaneous 2500 unit - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
- Gene Name
- SERPINC1
- Uniprot ID
- P01008
- Uniprot Name
- Antithrombin-III
- Molecular Weight
- 52601.935 Da
References
- Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Vascular endothelial growth factor receptor binding
- Specific Function
- Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
- Gene Name
- VEGFA
- Uniprot ID
- P15692
- Uniprot Name
- Vascular endothelial growth factor A
- Molecular Weight
- 27042.205 Da
References
- Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010 Oct 12. [PubMed:21091776 ]
- Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10. [PubMed:17692905 ]
- Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action...
- Gene Name
- TFPI
- Uniprot ID
- P10646
- Uniprot Name
- Tissue factor pathway inhibitor
- Molecular Weight
- 35014.835 Da
References
- Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev. 2004 Summer;22(2):121-34. [PubMed:15179449 ]
- Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M: Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. Epub 2010 Aug 3. [PubMed:20682597 ]
- Bendz B, Andersen TO, Sandset PM: Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. [PubMed:10847421 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sialic acid binding
- Specific Function
- Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligan...
- Gene Name
- SELP
- Uniprot ID
- P16109
- Uniprot Name
- P-selectin
- Molecular Weight
- 90833.105 Da
References
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Syndecan binding
- Specific Function
- Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Se...
- Gene Name
- HPSE
- Uniprot ID
- Q9Y251
- Uniprot Name
- Heparanase
- Molecular Weight
- 61148.17 Da
References
- Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398 ]
Drug created on September 14, 2010 10:21 / Updated on June 21, 2017 11:19